Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have taken a huge beating. In some cases, the markets have knocked valuations down into almost value…
Two recent Wedbush research reports focus is on health care companies that not only have data that could prove to be huge, but that have both been absolutely hammered over the past year.
Nymox Pharmaceutical shares made solid headway in Wednesday’s session on positive results from a cancer trial.
Medgenics saw its shares drop on Tuesday after the company announced the pricing of its secondary offering.
Impax Laboratories plans to take on a substantial portfolio of generic drugs in a transaction that will be immediately accretive and allow for accelerating growth in the years to come.
Health care costs could be $2.6 trillion less from 2014 to 2019, well below earlier forecasts, according to the Robert Wood Johnson Foundation.
Global Blood Therapeutics shares saw a handy gain in the premarket on Tuesday, despite the company pricing its secondary offering below its previous price level.
These four biotech companies not only have data that could prove to be huge, but they have been absolutely hammered over the past year, offering aggressive accounts the best entry points in some time.
Shares of Gilead Sciences Inc. (NASDAQ: GILD) saw make a handy gain just off of their 52-week low following the release of preliminary data from its HIV treatment. After the stock dropped about 17.5% so far…
Selecta Biosciences intends to price more than 4 million shares in the range of $14 to $16 per share for an initial public offering valued up to more than $78 million.
Syros Pharmaceuticals expects to price 4 million shares in the range of $14 to $16 per share in an intial public offering valued up to more than $73 million.
Inovio Pharmaceuticals has announced that it received approval to initiate a Phase 1 human trial to evaluate its Zika DNA vaccine (GLS-5700) to prevent infection from the Zika virus.
Shares of Fate Therapeutics saw a healthy gain early on Monday following a key U.S. Food and Drug Administration (FDA) approval.
Paratek Pharmaceuticals saw its shares take a solid jump early on Friday after the results from its late-stage trial were released.
Shares of Tonix Pharmaceuticals slid in Thursday’s session after the company announced the pricing of its secondary offering.
